- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03282045
Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat
A Multicenter, Single-blind, Randomized, Placebo-controlled Comparative Study on Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® Spray and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat in Common Cold
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be conducted in approximately 3 centers in Bosnia Herzegovina and in 4 centers in Turkey.
Primary objective:
The primary objective of this study is to evaluate superiority of Lysobact Complete Spray® against placebo and non inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS).
Secondary objective(s):
- Safety evaluation of Lysobact Complete Spray®, Tantum Verde® Spray, Pharyngal® Oromucosal Spray, based on the frequency and nature of adverse events occurring during treatment period.
- Extent of change in difficulty in swallowing, evaluated on the basis of Difficulty in Swallowing Scale (DSS), on Day 2, Day 4 and Day 6, as compared with baseline.
- Extent of change in swollen throat evaluation based on Swollen Throat Scale (STS) on Day 2, Day 4 and Day 6, as compared with baseline.
- Change in frequency of study treatment applications on Day 2, Day 4 and Day 6, as compared with baseline.
Test product: Lysobact Complete Spray® Active comparator product: Tantum Verde® Spray Active comparator product: Pharyngal® Oromucosal Spray Placebo product: Placebo
Primary endpoint:
• Primary endpoint is the change from baseline to Day 6 in mean VAS score for STPIS.
Secondary endpoint(s):
Secondary endpoints are as follows:
- change from baseline to Day 6 in mean VAS score for DSS
- change from baseline to Day 6 in mean VAS score for SwoTS
- change from baseline to each visit (Day 2, Day 4, Day 6) for STPIS , DSS and SwoTS
- percent improvement from baseline to each visit (Day 2, Day 4, Day 6) for STPIS , DSS and SwoTS
- Incidence of adverse events and relationship to the study treatments
- Incidence of serious adverse events and relationship to the study treatments
Statistical methods:
All patients who have received at least one dose of any study medication will be included in the safety evaluation (safety population). Patients who have completed all visits according to the protocol will be included in the efficacy population. The superiority and inferiority of Lysobact Complete Spray® will be tested in hierarchical order by the comparison of the mean change of VAS scores [Sore Throat Pain Intensity Scale (STPIS)] from baseline to Day 2, 4 and 6.
Planned treatment duration is 5 days. Safety will be followed-up until Day 6. End of study is defined as the end of the follow up period for the last patient.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Banja Luka, Bosnia and Herzegovina, 78000
- University Clinical Center of the Republic of Srpska, ENT Clinic, Banja Luka, Bosnia and Herzegovina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with acute tonsillo-pharyngitis symptoms in common cold and by using a scale-based symptom Tonsillo-Pharyngitis Assessment (TPA) as an objective finding of pharyngeal infection, with a score of ≥5
- Patients who will be treated only on a symptomatic treatment basis, and with a prescribed a oropharyngeal spray
- Patients, 18 years of age and above, who provided an informed consent
- Patients with a sore-throat of recent onset, symptoms initiated ≤48 hours
- Patients with sore throat pain rated ≥66 mm on the Sore Throat Pain Intensity Scale (STPIS)
- Patients with difficulty in swallowing rated ≥50 mm on Difficulty Swallowing Scale (DSS)
- Patients with a sensation of swollen throat rated ≥33 mm on the Swollen Throat Scale (SwoTS)
Exclusion Criteria:
- Patients who had any previous (within 4 hours prior to screening examination) throat lozenge treatment/use
- Patients who had used any flu-preparation which contains any analgesic ingredient such as paracetamol, ibuprofen or acetylsalicylic acid (ASA) along with a decongestant
- Patients who had analgesic use (any) 4 hours prior to the screening examination
- Patients who are prescribed an antibiotic use before the screening visit and are entitled to use antibiotics during the course of this non-interventional study
- Patients with a known hypersensitivity to active/inactive ingredients of medications which is prescribed for the symptomatic treatment of sore throat
- Patients with known hypersensitiveness to egg white and other allergens
- Patients who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lysobact Complete Sprey
Lysobact Complete Sprey Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride. |
Inhaling spray
|
Active Comparator: Tantum Verde® Spray
Tantum Verde® Spray Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open. Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose. |
Inhaling spray
|
Active Comparator: Pharyngal® Oromucosal Spray
Pharyngal® Oromucosal Spray Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open. Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride. |
Inhaling spray
|
Placebo Comparator: Placebo
Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open. Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times. |
Inhaling spray
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
to evaluate superiority of Lysobact Complete Spray® against placebo and non-inferiority of Lysobact Complete Spray® against active comparators
Time Frame: Day 6
|
The primary objective of this study is to evaluate superiority of Lysobact Complete Spray® against placebo and non-inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS).
|
Day 6
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: OZGUN ENVER, MD, Istanbul University-Cerrahpasa School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOS_CS_01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sore Throat
-
Sohag UniversityNot yet recruiting
-
Menoufia UniversityRecruitingPostoperative Sore ThroatEgypt
-
University of VermontCompletedSore Throat | Post-Operative Sore ThroatUnited States
-
Seoul National University HospitalCompletedPostoperative Sore ThroatKorea, Republic of
-
Yonsei UniversityCompleted
-
Pharos University in AlexandriaRecruiting
-
Sir Ganga Ram HospitalRecruitingPostoperative Sore ThroatIndia
-
Alaa GamalRecruitingPostoperative Sore ThroatEgypt
-
Rehman Medical Institute - RMIRecruiting
-
Yeungnam University College of MedicineCompleted
Clinical Trials on Lysobact Complete Sprey
-
Yeditepe UniversityCompletedLocal Anesthesia | Cannula Site PainTurkey
-
University of North Carolina, Chapel HillGlobal Dental Science, LLCWithdrawnMouth, EdentulousUnited States
-
Ain Shams UniversityNot yet recruitingComplete EdentulismEgypt
-
Fatma mahannaCompleted
-
Zimmer BiometCompletedOsteoarthritis | Rheumatoid Arthritis | Avascular Necrosis | Traumatic Arthritis | Legg-Perthes DiseaseKorea, Republic of
-
DePuy InternationalCompleted
-
RenJi HospitalRecruiting
-
Chonnam National University HospitalRecruitingMyocardial Infarction, Acute | Multi-Vessel Coronary Artery Stenosis | Multi Vessel Coronary Artery DiseaseKorea, Republic of
-
Cairo UniversityUnknown